Shanghai Securities News China Securities Network News (reporter Confucius Ziyuan) Yahong Pharmaceutical announced that the company received the "Drug Clinical Trial Approval Notice" issued by the State Drug Administration (NMPA), which is a prospective, self-controlled multicenter Phase III clinical trial to explore the additional detection rate and safety of Heckway combined blue cystoscopy versus white light cystoscopy for non-muscular invasive bladder cancer (NMIBC) (carcinoma in situ (CIS), Ta, T1). In the future, the company will submit a product listing application to the State Drug Administration based on the progress of the clinical trial and the effective data.
Heckway is currently the only approved developer drug in the world to assist in the diagnosis or surgery of bladder cancer, and through the combination of blue cystoscopy, it can effectively improve the detection rate of NMMIBC (especially the detection rate of carcinoma in situ), make surgical resection more complete, and thus reduce the tumor recurrence rate. Hecway has been approved in many countries in the United States and Europe.
![Yahong Pharmaceutical: APL-1202 and Bai Zean combined neoadjuvant therapy completed the world's first drug administration in the United States[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)